Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-011 +/- Budigalimab in SCLC
NCT03639194Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2018
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of ABBV-011 in small cell lung cancer (SCLC) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants With Adverse Events up to 5 years, Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RPTD) of ABBV-011 up to 5 years and 5 more. Started Oct 2018; status: completed.
02
Drugs
ABBV-011
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03639194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639194.